None listed
Conditions
Interventions
Drug : 1. JaQbo group: JaQbo Tab., 20 mg, once a day, 6 months, Per Os
2. A placebo that looks exactly 'JaQbo Tab. 20 mg' shape and has no medicinal effect, once a day, 6 months, Per Os
Sponsors
Samsung Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Adults over the age of 19 2) Patients who have agreed to study gastrointestinal protection while receiving antiplatelet (aspirin or P2Y12 receptor blocker) or anticoagulant (warfarin or NOAC) treatment (1) a patient on Antiplatelet drugs have already been used to prevent and treat blood clots in patients with cardiovascular disease, cerebrovascular disease, and peripheral arterial disease (2) To prevent retraction after coronary stent procedure due to acute myocardial infarction, antiplatelet drugs have already been taken a patient, (3) Patients who are already taking anticoagulants to prevent stroke in patients with atrial fibrillation, (4) Patients who are already taking anticoagulants to treat deep vein thrombosis and pulmonary embolism, or (5) Patients who have undergone heart valve procedures (or surgery) and are already taking anticoagulants for the prevention of blood clots
Exclusion criteria
Exclusion criteria: 1) A person who is deemed difficult to continue antithrombotic treatment by a clinician due to repeated bleeding history (intracerebral hemorrhage, gastrointestinal bleeding, hematuria, hematopoiesis, etc.) or risk of bleeding 2) Sensitive to antiplatelet drugs, anticoagulants, or JaQbo 3) When antiplatelet drugs and anticoagulants are used in combination 4) Study registration If patients have taken a gastric acid secretion inhibitor (PPI or P-CAB) at least once within 4 weeks 5) Using atazanavir, nelfinavir, or Ripivirine containing medications 6) Because this drug contains lactose, patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption 7) Liver disease 8 Renal failure 9) If suspected malignancy (significant unintended weight loss, recurrent vomiting, difficulty swallowing, hemoptysis, melena, etc.) and have a gastric ulcer 10) Taking nonsteroidal anti-inflammatory drugs (NSAIDs; aceclofenac, meloxicam, naproxen) 11) Taking CYP3A4/CYP3A5 inducer and inhibitor 12) Taking clarithromycin and amoxicillin together 13) Pregnant or Breastfeeding 14) Women of childbearing age who have a pregnancy plan during the study period 15) A person whose life expectancy is less than 6 months 16) Other persons deemed unfit by the tester to participate in this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of upper gastrointestinal bleeding events | — |
Secondary
| Measure | Time frame |
|---|---|
| Upper gastrointestinal symptoms such as heartburn, epigastric pain, nausea or vomiting, frequent belching or abdominal bloating, bitterness or coming over, or upper gastrointestinal symptoms, etc. | — |
Countries
Korea, Republic of
Contacts
Public ContactSung-Ji Park
Samsung Medical Center
Outcome results
None listed